Active — Not RecruitingPhase 1

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

United States130 participantsStarted 2022-03-31

Plain-language summary

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * Adequate bone marrow, kidney and liver function * Performance status of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement. Exclusion Criteria: * Prior treatment targeting ILT3. * Prior treatment targeting LAIR1.

What they're measuring

Number of Patients with Dose-limiting Toxicities

Timeframe: Baseline up to 21 Days

Incidence of Adverse Events

Timeframe: Baseline up to Approximately 24 months

Trial details

NCT IDNCT05215574

SponsorNGM Biopharmaceuticals, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-07

View on ClinicalTrials.gov More Pancreatic Cancer trials